Skip to main content
    C

    CNS Pharmaceuticals Inc (CNSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.48
    +0.59 (+20.42%)

    Market Cap: $4.22M

    Last updated: Nov 17, 2026 at 10:56 AM ET

    CNS Pharmaceuticals Inc (CNSP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    CNS Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$15.85M, operating cash flow was -$13.81M and free cash flow was -$13.83M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.50M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $15.99M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Research and development$9.77M$9.29M$14.10M$9.30M$9.81M$5.06M$1.85M$21.27K$32.64K
    Operating income-$15.99M-$14.90M-$18.87M-$15.27M-$14.49M-$9.45M-$3.83M-$881.79K-$516.25K
    Net income-$15.85M-$14.86M-$18.85M-$15.27M-$14.50M-$9.46M-$3.88M-$7.39M-$526.47K
    EBITDA-$15.83M-$14.84M-$18.83M-$14.92M-$14.47M-$9.44M-$3.71MN/AN/A
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.14K$0$0$0$0
    Gross profit$0$0$0$2.90K$0$0$0-$985$0$0$0N/A
    Operating income-$2.67M-$2.70M-$4.98M-$5.99M-$3.25M-$2.41M-$4.34M-$3.20M-$5.63M-$2.53M-$3.54M-$5.38M
    Net income-$2.50M-$2.59M-$4.94M-$5.96M-$3.22M-$2.38M-$4.30M-$3.18M-$5.61M-$2.53M-$3.54M-$5.38M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $328.00K by $6.87M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$8.62M$8.70M$1.70M$13.05M$8.76M$15.85M$7.91M$683.33K$162.19K
    Current assets$8.10M$8.66M$1.59M$12.56M$7.48M$15.50M$7.89M$588.13K$162.19K
    Cash and equivalents$7.20M$6.46M$548.72K$10.06M$5.00M$14.04M$7.24M$282.74K$110.54K
    Total liabilities$4.10M$2.52M$6.13M$4.92M$2.59M$1.91M$311.00K$1.23M$220.73K
    Short-term debt$328.00K$326.07K$300.81K$409.97K$387.79K$439.29K$0$316.92K$121.83K
    Shareholder equity$4.52M$6.18M-$4.43M$8.13M$6.16M$13.95M$7.60M-$549.30K-$58.53K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$18.06M$21.94M$4.65M$8.62M$11.87M$14.51M$13.75M$8.70M$7.41M$2.47M$1.66M$1.70M
    Total liabilities$2.36M$3.74M$4.58M$4.10M$1.96M$1.38M$2.78M$2.52M$4.06M$6.76M$6.09M$6.13M
    Cash and equivalents$17.21M$19.98M$2.95M$7.20M$9.86M$12.13M$13.05M$6.46M$6.97M$1.49M$815.23K$548.72K
    Shareholder equity$15.71M$18.20M$70.70K$4.52M$9.91M$13.12M$10.97M$6.18M$3.35M-$4.29M-$4.43M-$4.43M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$13.81M-$17.11M-$14.14M-$10.56M-$13.54M-$7.32M-$3.55M-$716.38K-$112.20K
    Capital expenditures$18.18K$4.19K$3.90K$4.42K$5.75K$17.95K$20.12K$0$3
    Free cash flow-$13.83M-$17.12M-$14.14M-$10.56M-$13.54M-$7.34M-$3.57M-$716.38K-$112.20K
    Share repurchases$2.04K$0N/AN/AN/AN/AN/A$21.00KN/A
    Investing cash flow-$18.18K-$4.19K-$3.90K-$4.42K-$5.75K-$17.95K-$20.12K$0-$20.12K
    Financing cash flow$14.57M$23.03M$4.64M$15.61M$4.51M$14.13M$10.26M$1.16M$222.74K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.77M-$3.54M-$4.65M-$3.05M-$2.17M-$5.34M-$3.24M-$5.47M-$6.80M-$1.65M-$3.19M-$2.54M
    Capital expendituresN/A$3.82K$6.18K$18.18K$0$0$0$4.19K$3$3$3$2.16K
    Free cash flowN/A-$3.54M-$4.65M-$3.07M-$2.17M-$5.34M-$3.24M-$5.48M-$6.80M-$1.65M-$3.19M-$2.54M
    Last 12 quarters

    Frequently Asked Questions About CNSP

    What is CNS Pharmaceuticals' annual revenue?

    CNS Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is CNS Pharmaceuticals profitable?

    No. CNS Pharmaceuticals reported net income of -$15.85M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CNSP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.81M minus capital expenditures of $18.18K produced free cash flow of -$13.83M.

    How much debt does CNS Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $328.00K and cash and equivalents of $7.20M.